Page 193 - Read Online

203. Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, and molecular carcinogenesis. Gastroenterology 2007;132:2557-
Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, Autran 76.
B, Cosset FL, Strick-Marchand H, Trépo C, Kao JH, Carrat F, 225. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral
Lacombe K, Schinazi RF, Barre-Sinoussi F, Delfraissy JF, Zoulim oncology of hepatocellular carcinoma. Oncogene 2003;22:5093-
F. Towards an HBV cure: state-of-the-art and unresolved questions- 107.
-report of the ANRS workshop on HBV cure. Gut 2015;64:1314-26. 226. McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular
204. Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis carcinoma. Clin Liver Dis 2010;14:461-76.
K, Lohmann V, Mier W, Mehrle S, Urban S. Cyclosporin A inhibits 227. Bagga S, Bouchard MJ. Cell cycle regulation during viral infection.
hepatitis B and hepatitis D virus entry by cyclophilin-independent Methods Mol Biol 2014;1170:165-227.
interference with the NTCP receptor. J Hepatol 2014;60:723-31. 228. Casciano JC, Bagga S, Yang B, Bouchard MJ. Modulation of cell
205. Yan H, Liu Y, Sui J, Li W. NTCP opens the door for hepatitis B virus proliferation pathways by the hepatitis B virus X protein: a potential
infection. Antiviral Res 2015;121:24-30. contributor to the development of hepatocellular carcinoma. In: Lau
206. Shlomai A, Schwartz RE, Ramanan V, Bhatta A, de Jong YP, WY, editor. Hepatocellular carcinoma - basic research. Shanghai,
Bhatia SN, Rice CM. Modeling host interactions with hepatitis China: InTech; 2011. p. 103-53.
B virus using primary and induced pluripotent stem cell-derived 229. Rawat S, Clippinger AJ, Bouchard MJ. Modulation of apoptotic
hepatocellular systems. Proc Natl Acad Sci U S A 2014;111:12193- signaling by the hepatitis B virus X protein. Viruses 2012;4:2945-
8. 72.
207. Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related 230. Lamontagne J, Steel LF, Bouchard MJ. Hepatitis B virus and
hepatocarcinogenesis. J Hepatol 2010;52:594-604. microRNAs: complex interactions affecting hepatitis B virus
208. Clippinger AJ, Bouchard MJ. Hepatitis B virus HBx protein replication and hepatitis B virus-associated diseases. World J
localizes to mitochondria in primary rat hepatocytes and modulates Gastroenterol 2015;21:7375-99.
mitochondrial membrane potential. J Virol 2008;82:6798-811. 231. Panteva M, Korkaya H, Jameel S. Hepatitis viruses and the MAPK
209. Chen CJ, Yang HI. Natural history of chronic hepatitis B revealed. J pathway: is this a survival strategy? Virus Res 2003;92:131-40.
Gastroenterol Hepatol 2011;26:628-38. 232. Wang Z, Jin W, Jin H, Wang X. mTOR in viral hepatitis and
210. Guy CS, Mulrooney-Cousins PM, Churchill ND, Michalak TI. hepatocellular carcinoma: function and treatment. Biomed Res Int
Intrahepatic expression of genes affiliated with innate and adaptive 2014;2014:735672.
immune responses immediately after invasion and during acute 233. Guo H, Zhou T, Jiang D, Cuconati A, Xiao GH, Block TM,
infection with woodchuck hepadnavirus. J Virol 2008;82:8579-91. Guo JT. Regulation of hepatitis B virus replication by the
211. Wieland SF, Spangenberg HC, Thimme R, Purcell RH, Chisari FV. phosphatidylinositol 3-kinase-akt signal transduction pathway. J
Expansion and contraction of the hepatitis B virus transcriptional Virol 2007;81:10072-80.
template in infected chimpanzees. Proc Natl Acad Sci U S A 234. Friedrich B, Wollersheim M, Brandenburg B, Foerste R, Will H,
2004;101:2129-34. Hildt E. Induction of anti-proliferative mechanisms in hepatitis B
212. Summers J, Mason WS. Residual integrated viral DNA after virus producing cells. J Hepatol 2005;43:696-703.
hepadnavirus clearance by nucleoside analog therapy. Proc Natl 235. Wang CM, Wang Y, Fan CG, Xu FF, Sun WS, Liu YG, Jia JH.
Acad Sci U S A 2004;101:638-40. miR-29c targets TNFAIP3, inhibits cell proliferation and induces
213. Schultz U, Summers J, Staeheli P, Chisari FV. Elimination of duck apoptosis in hepatitis B virus-related hepatocellular carcinoma.
hepatitis B virus RNA-containing capsids in duck interferon-alpha- Biochem Biophys Res Commun 2011;411:586-92.
treated hepatocytes. J Virol 1999;73:5459-65. 236. Chin R, Earnest-Silveira L, Koeberlein B, Franz S, Zentgraf H, Dong
214. Guo JT, Pryce M, Wang X, Barrasa MI, Hu J, Seeger C. Conditional X, Gowans E, Bock CT, Torresi J. Modulation of MAPK pathways
replication of duck hepatitis B virus in hepatoma cells. J Virol and cell cycle by replicating hepatitis B virus: factors contributing
2003;77:1885-93. to hepatocarcinogenesis. J Hepatol 2007;47:325-37.
215. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus 237. Huang YQ, Wang LW, Yan SN, Gong ZJ. Effects of cell cycle on
infection: what we knew in 1981 and what we know in 2005. telomerase activity and on hepatitis B virus replication in HepG2
Hepatology 2006;43:S173-81. 2.2.15 cells. Hepatobiliary Pancreat Dis Int 2004;3:543-7.
216. Blackberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute 238. Ozer A, Khaoustov VI, Mearns M, Lewis DE, Genta RM, Darlington
self-limited infection persisting for 30 years without sequence GJ, Yoffe B. Effect of hepatocyte proliferation and cellular DNA
variation. J Hepatol 2000;33:992-7. synthesis on hepatitis B virus replication. Gastroenterology
217. Chazouillères O, Mamish D, Kim M, Carey K, Ferrell L, Roberts 1996;110:1519-28.
JP, Ascher NL, Wright TL. “Occult” hepatitis B virus as source of 239. Qiao L, Leach K, McKinstry R, Gilfor D, Yacoub A, Park JS, Grant
infection in liver transplant recipients. Lancet 1994;343:142-6. S, Hylemon PB, Fisher PB, Dent P. Hepatitis B virus X protein
218. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, increases expression of p21(Cip-1/WAF1/MDA6) and p27(Kip-1)
Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G. in primary mouse hepatocytes, leading to reduced cell cycle
Hepatitis B virus maintains its pro-oncogenic properties in the case progression. Hepatology 2001;34:906-17.
of occult HBV infection. Gastroenterology 2004;126:102-10. 240. Shlomai A, Shaul Y. The “metabolovirus” model of hepatitis B virus
219. Gish RG, Given BD, Lai CL, Locarnini SA, Lau JY, Lewis DL, suggests nutritional therapy as an effective anti-viral weapon. Med
Schluep T. Chronic hepatitis B: virology, natural history, current Hypotheses 2008;71:53-7.
management and a glimpse at future opportunities. Antiviral Res 241. Popescu CI, Riva L, Vlaicu O, Farhat R, Rouille Y, Dubuisson J.
2015;121:47-58. Hepatitis C virus life cycle and lipid metabolism. Biology (Basel)
220. Chang ML, Liaw YF. Hepatitis B flares in chronic hepatitis 2014;3:892-921.
B: pathogenesis, natural course, and management. J Hepatol 242. Yan H, Peng B, Liu Y, Xu G, He W, Ren B, Jing Z, Sui J, Li W.
2014;61:1407-17. Viral entry of hepatitis B and D viruses and bile salts transportation
221. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis share common molecular determinants on sodium taurocholate
in patients with chronic type B hepatitis: a prospective study. cotransporting polypeptide. J Virol 2014;88:3273-84.
Hepatology 1988;8:493-6. 243. Reese VC, Moore DD, McLachlan A. Limited effects of bile acids
222. Globocan 2012 v1.0 [Internet]. IARC CancerBase No. 11. 2013. and small heterodimer partner on hepatitis B virus biosynthesis in
Available from: http://globocan.iarc.fr vivo. J Virol 2012;86:2760-8.
223. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular 244. Waris G, Siddiqui A. Interaction between STAT-3 and HNF-3
carcinoma. Gastroenterology 2012;142:1264-73. leads to the activation of liver-specific hepatitis B virus enhancer 1
224. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology function. J Virol 2002;76:2721-9.
184 Hepatoma Research | Volume 2 | July 1, 2016